Eli Lilly Invests Over $1 Billion to Boost Manufacturing in India

Eli Lilly, the US-based pharmaceutical giant, announced on October 6, 2023, plans to invest more than $1 billion in India over the coming years. This significant investment aims to enhance manufacturing capabilities and supply chains through partnerships with local drug manufacturers. The move aligns with Lilly’s strategy to leverage India’s skilled workforce as part of its broader global manufacturing expansion.

The investment is designed to increase the availability of Lilly’s key medications, which address conditions such as obesity, diabetes, Alzheimer’s disease, cancer, and autoimmune disorders. According to Patrik Jonsson, president of Lilly International, “We are making significant investments to increase manufacturing and medicine supply capacity around the world.” He emphasized that India serves as a vital hub for capability building within the company’s global network.

At present, Eli Lilly does not operate its own manufacturing facility in India. Instead, the company collaborates with several local firms that specialize in developing and manufacturing complex drugs, vials, and injectables on a contract basis. Lilly confirmed its active engagement with contract manufacturers in India but did not provide additional specifics regarding these partnerships.

Strategic Timing Amid Global Changes

Lilly’s investment in India coincides with a period when many global pharmaceutical companies are focusing on expanding their manufacturing capabilities in the United States. This shift follows the implementation of a 100 percent tariff on imported branded and patented drugs, which took effect on October 1, 2023. Last month, Lilly also announced a $5 billion investment in a new facility in Virginia as part of a broader $27 billion expansion plan to establish four new plants in the United States over the next five years.

The launch of Lilly’s weight-loss drug, Mounjaro, in India earlier this year has already sparked heightened awareness of obesity treatments in a country projected to have the world’s second-largest population of individuals living with obesity by 2050. Sales of both Mounjaro and Wegovy, produced by Danish drugmaker Novo Nordisk, have reportedly doubled within months of their introduction to the Indian market.

As competition intensifies, especially from India’s generic drug manufacturers, Lilly is preparing for the potential launch of more affordable versions of Wegovy. This is anticipated to occur once its primary active ingredient, semaglutide, goes off patent next year, further fueling interest in obesity treatments.

New Facility in Hyderabad

In addition to its broader investment strategy, Lilly is establishing a manufacturing and quality facility in Hyderabad. This new hub will expand the company’s presence beyond its existing global capability center in the city. The facility will oversee Lilly’s contract manufacturing network across India and enhance its technical capabilities.

Recruitment for the new site will commence immediately, with plans to hire professionals such as engineers, chemists, analytical scientists, and quality control and assurance experts. Lilly’s commitment to expanding its operations in India reflects the company’s confidence in the region’s potential to support its global manufacturing objectives while addressing local healthcare needs.